Corcept Therapeutics Incorporated
CORT
$57.08
$5.9211.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 164.90M | 202.13M | 207.64M | 194.43M | 157.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.90M | 202.13M | 207.64M | 194.43M | 157.21M |
| Cost of Revenue | 2.88M | 2.55M | 4.60M | 3.43M | 2.40M |
| Gross Profit | 162.02M | 199.58M | 203.04M | 191.00M | 154.81M |
| SG&A Expenses | 145.36M | 130.24M | 123.98M | 103.85M | 90.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.50M | 197.64M | 197.42M | 167.76M | 153.80M |
| Operating Income | -49.60M | 4.49M | 10.22M | 26.68M | 3.42M |
| Income Before Tax | -44.72M | 9.91M | 15.24M | 31.69M | 9.62M |
| Income Tax Expenses | -12.95M | -14.38M | -4.43M | -3.46M | -10.93M |
| Earnings from Continuing Operations | -31.76M | 24.29M | 19.67M | 35.15M | 20.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.76M | 24.29M | 19.67M | 35.15M | 20.55M |
| EBIT | -49.60M | 4.49M | 10.22M | 26.68M | 3.42M |
| EBITDA | -49.00M | 4.78M | 10.51M | 26.96M | 3.88M |
| EPS Basic | -0.30 | 0.23 | 0.19 | 0.33 | 0.19 |
| Normalized Basic EPS | -0.27 | 0.06 | 0.09 | 0.19 | 0.06 |
| EPS Diluted | -0.30 | 0.20 | 0.16 | 0.29 | 0.17 |
| Normalized Diluted EPS | -0.27 | 0.05 | 0.08 | 0.16 | 0.05 |
| Average Basic Shares Outstanding | 104.44M | 103.70M | 103.55M | 104.11M | 104.11M |
| Average Diluted Shares Outstanding | 104.44M | 119.86M | 119.44M | 120.49M | 119.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |